The PARS2 antibody is a specialized immunological tool designed to detect and study Prolyl-tRNA synthetase 2, mitochondrial (PARS2), a protein critical for mitochondrial translation and oxidative phosphorylation. PARS2 catalyzes the attachment of proline to its cognate tRNA, a step essential for mitochondrial protein synthesis . Dysregulation of PARS2 is linked to mitochondrial disorders, including early infantile epileptic encephalopathy (EIEE75) and cardiomyopathy . Antibodies targeting PARS2 enable researchers to investigate its expression, localization, and functional roles in health and disease.
The CAB16512 antibody targets a 190-amino acid region (residues 30–220) of PARS2, ensuring high specificity for mitochondrial isoforms .
Proteintech’s 15864-1-AP uses a fusion protein immunogen, validated for consistent reactivity across species .
Blocking Assays: The NBP2-54971PEP recombinant antigen is used to confirm antibody specificity by competing with endogenous PARS2 in binding assays .
Disease Research: Antibodies like CAB16512 have been employed in studies identifying PARS2 mutations in mitochondrial cardiomyopathy .
Cardiomyopathy: A 2024 study identified novel PARS2 compound heterozygous variants (c.283G>A and c.953C>T) in a patient with lethal cardiomyopathy, validated using PARS2 antibodies in protein expression analyses .
Neurological Disease: Antibodies detected reduced PARS2 levels in brain tissues of patients with developmental delay and seizures .
Subcellular Distribution: The Human Protein Atlas confirms PARS2’s mitochondrial localization using IHC and immunofluorescence .
Diagnostic Use: PARS2 antibodies aid in diagnosing EIEE75 and cardiomyopathy by identifying protein expression anomalies .
Therapeutic Targets: Research using these antibodies highlights PARS2’s role in mitochondrial bioenergetics, suggesting potential for antioxidant therapies to mitigate disease progression .